dc.date.accessioned2019-02-06T14:52:36Z
dc.date.available2019-02-06T14:52:36Z
dc.date.created2019-02-06T14:52:36Z
dc.date.issued2015
dc.identifierhttps://hdl.handle.net/20.500.12866/5322
dc.identifierhttps://doi.org/10.1161/HYPERTENSIONAHA.114.05003
dc.description.abstractUNLABELLED: Blood pressure increases during acute exposure to high altitude in healthy humans. However, little is known on altitude effects in hypertensive subjects or on the treatment efficacy in this condition. Objectives of High Altitude Cardiovascular Research (HIGHCARE)-Andes Lowlanders Study were to investigate the effects of acute high-altitude exposure on 24-hour ambulatory blood pressure in hypertensive subjects and to assess antihypertensive treatment efficacy in this setting. One hundred untreated subjects with mild hypertension (screening blood pressure, 144.1+/-9.8 mm Hg systolic, 92.0+/-7.5 mm Hg diastolic) were randomized to double-blind placebo or to telmisartan 80 mg+modified release nifedipine 30 mg combination. Twenty-four-hour ambulatory blood pressure monitoring was performed off-treatment, after 6 weeks of treatment at sea level, on treatment during acute exposure to high altitude (3260 m) and immediately after return to sea level. Eighty-nine patients completed the study (age, 56.4+/-17.6 years; 52 men/37 women; body mass index, 28.2+/-3.5 kg/m(2)). Twenty-four-hour systolic blood pressure increased at high altitude in both groups (placebo, 11.0+/-9 mm Hg; P<0.001 and active treatment, 8.1+/-10.4 mm Hg; P<0.001). Active treatment reduced 24-hour systolic blood pressure both at sea level and at high altitude (147.9+/-11.1 versus 132.6+/-12.4 mm Hg for placebo versus treated; P<0.001; 95% confidence interval of the difference 10.9-19.9 mm Hg) and was well tolerated. Similar results were obtained for diastolic, for daytime blood pressure, and for nighttime blood pressure. Treatment was well tolerated in all conditions. Our study demonstrates that (1) 24-hour blood pressure increases significantly during acute high-altitude exposure in hypertensive subjects and (2) treatment with angiotensin receptor blocker-calcium channel blocker combination is effective and safe in this condition.
dc.languageeng
dc.publisherWolters Kluwer Health
dc.relationHypertension
dc.relation1524-4563
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAdult
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectAltitude
dc.subjectTreatment Outcome
dc.subjectSeverity of Illness Index
dc.subjectRisk Assessment
dc.subjectblood pressure
dc.subjectaltitude
dc.subjectConfidence Intervals
dc.subjectDouble-Blind Method
dc.subjectAntihypertensive Agents/therapeutic use
dc.subjectReference Values
dc.subjectanoxia
dc.subjectantihypertensive agents
dc.subjectBlood Pressure Determination/methods
dc.subjectblood pressure monitoring, ambulatory
dc.subjectBlood Pressure Monitoring, Ambulatory/methods
dc.subjectHypertension/diagnosis/drug therapy
dc.titleAmbulatory blood pressure in untreated and treated hypertensive patients at high altitude: the High Altitude Cardiovascular Research-Andes study
dc.typeinfo:eu-repo/semantics/article


Este ítem pertenece a la siguiente institución